Colorado attained a number of key financings, acquisitions and
expansions in the bioscience industry during 2014. The announcement is
made by April Giles, President and CEO of the Colorado BioScience
Association (CBSA), who says: "We’ve seen a number of exciting deals
come to fruition in our Colorado bioscience community during 2014, which
strengthens our state’s position as a national industry leader. We’re
thrilled that CBSA has continued to play a significant role in promoting
Colorado as a dynamic region for bioscience innovation and investment.”
Highlighted Financings and Acquisitions in 2014 Include:
-
Terumo BCT broke ground on a 120,000-square-foot global
headquarters building – April 1, 2014
Terumo BCT is building
a 120,000-square-foot Global Headquarters building on its Lakewood
campus. In 2015, when the building opens, Terumo BCT will occupy
90,000 square feet, leaving the additional space available for future
growth and development. When complete, it will accommodate an
estimated 400 associates. http://coloradocommunitymedia.com/stories/A-global-home,151084
-
BioScience Park Center 2 groundbreaking adding 112,000-square-foot
building – April 4, 2014
The Fitzsimons Redevelopment
Authority (FRA) and CU's Bioengineering program design a multipurpose
building for education, research and clinical care, with an added
entrepreneurial element of private biosciences companies.
Bioengineering students will have classes on the first two floors of
the four-story building, and from there, the students will move up a
floor and practice what they have learned and then move up again to
begin their own commercial bioscience company on the top floor. http://www.ucdenver.edu/about/newsroom/newsreleases/Pages/Bioscience-2-groundbreaking-April-2014.aspx
-
Covidien to be acquired by Medtronic for $42.9B – June 16, 2014
Medtronic
announced it will pay $42.9 billion in cash and stock to acquire
Covidien and its medical-device lines in a deal expected to close in
the fourth quarter or early 2015. Medtronic in Louisville, and
Covidien in Boulder, combined have over 2,000 jobs in Colorado. http://www.massdevice.com/news/blockbuster-medtronic-43b-deal-acquire-covidien
-
Clovis Oncology to offer $200M in convertible senior notes in
private placement to investors – Sept 3, 2014
Boulder-based
Clovis Oncology Inc. announced it intended to offer $200 million
aggregate principal amount of its convertible senior notes due 2021 in
a private placement to qualified international buyers. http://innovationews.com/science/bioscience/clovis-oncology-to-offer-200m-in-convertible-senior-notes-in-private-placement-to-foreign-investors
-
InDevR wins $14.7M BARDA contract for cutting-edge influenza
diagnostic – September 15, 2014
Boulder-based InDevR
announced that it signed a contract with the Biomedical Advanced
Research and Development Authority (BARDA) to complete product
development of their unique influenza diagnostic, FluChip-8G, which is
capable of rapidly genotyping influenza viruses directly from clinical
samples. http://www.marketwired.com/press-release/-1947252.htm
-
SomaLogic announces Novartis agreement extension, equity investment
– October 20, 2014
Boulder-based SomaLogic, Inc. announced
that Novartis has extended its multi-year research agreement for the
development and application of SomaLogic’s unique proteomics
technology to Novartis’ drug discovery and development efforts.
Novartis will also take an equity position in SomaLogic under the
agreement extension. http://www.somalogic.com/Resources/News-Events/News/2014/SomaLogic-announces-Novartis-agreement-extension,.aspx
-
N30 Pharmaceuticals secures $30 million in oversubscribed crossover
financing – November 19, 2014
Boulder-based N30
Pharmaceuticals, Inc. (“N30 Pharma”), a clinical stage,
biopharmaceutical company focused on the development of therapies for
cystic fibrosis (CF), has raised $30 million in a mezzanine round of
financing. Proceeds from the financing will primarily be used to
advance the Company’s clinical trial program. New investors include
Wellington Management, RA Capital Management, LLC, Jennison Associates
LLC (on behalf of certain clients), Rock Springs Capital Management
LP, and Sabby Management, LLC, who joined existing investor, Deerfield
Management Company. http://www.prnewswire.com/news-releases/n30-pharmaceuticals-secures-30-million-in-oversubscribed-crossover-financing-283193921.html
About Colorado BioScience Association
The CBSA is a not-for-profit organization providing services and support
for Colorado's growing biosciences industry. With more than 350 members,
CBSA actively works to promote the growth of the industry by working for
a better business environment, grow the state's biotech workforce, fight
for policies that support a strong bioscience industry in the state, and
speaking with a single voice on behalf of the industry. For more
information, visit http://www.cobioscience.com.
CBSA also is found on these social media sites:
Twitter: http://www.twitter.com/COBioscience
LinkedIn
Group: http://www.linkedin.com/groups?about=&gid=98468&trk=anet_ug_grppro
Facebook
Fan Page: http://www.facebook.com/ColoradoBioScienceAssociation
Blogger:
http://coloradobio.blogspot.com
YouTube:
http://www.youtube.com/COBioscience
Pinterest:
http://pinterest.com/COBioscience
Google+:
https://plus.google.com/u/0/101998361861247247369/posts
Tumblr:
http://cobioscience.tumblr.com
Instagram:
http://instagram.com/coloradobioscience
Copyright Business Wire 2014